Clinical and parasitological response to oral chloroquine and primaquine in uncomplicated human Plasmodium knowlesi infections by Daneshvar, Cyrus et al.
RESEARCH Open Access
Clinical and parasitological response to oral
chloroquine and primaquine in uncomplicated
human Plasmodium knowlesi infections
Cyrus Daneshvar1, Timothy ME Davis2, Janet Cox-Singh1, Mohammad Z Rafa’ee3, Siti K Zakaria1, Paul CS Divis1,
Balbir Singh1*
Abstract
Background: Plasmodium knowlesi is a cause of symptomatic and potentially fatal infections in humans. There are
no studies assessing the detailed parasitological response to treatment of knowlesi malaria infections in man and
whether antimalarial resistance occurs.
Methods: A prospective observational study of oral chloroquine and primaquine therapy was conducted in
consecutive patients admitted to Kapit Hospital, Sarawak, Malaysian Borneo with PCR-confirmed single P. knowlesi
infections. These patients were given oral chloroquine for three days, and at 24 hours oral primaquine was
administered for two consecutive days, primarily as a gametocidal agent. Clinical and parasitological responses
were recorded at 6-hourly intervals during the first 24 hours, daily until discharge and then weekly to day 28. Vivax
malaria patients were studied as a comparator group.
Results: Of 96 knowlesi malaria patients who met the study criteria, 73 were recruited to an assessment of the
acute response to treatment and 60 completed follow-up over 28 days. On admission, the mean parasite stage
distributions were 49.5%, 41.5%, 4.0% and 5.6% for early trophozoites, late trophozoites, schizonts and gametocytes
respectively. The median fever clearance time was 26.5 [inter-quartile range 16-34] hours. The mean times to 50%
(PCT50) and 90% (PCT90) parasite clearance were 3.1 (95% confidence intervals [CI] 2.8-3.4) hours and 10.3 (9.4-11.4)
hours. These were more rapid than in a group of 23 patients with vivax malaria 6.3 (5.3-7.8) hours and 20.9 (17.6-
25.9) hours; P = 0.02). It was difficult to assess the effect of primaquine on P. knowlesi parasites, due to the rapid
anti-malarial properties of chloroquine and since primaquine was administered 24 hours after chloroquine. No
P. knowlesi recrudescences or re-infections were detected by PCR.
Conclusions: Chloroquine plus primaqine is an inexpensive and highly effective treatment for uncomplicated
knowlesi malaria infections in humans and there is no evidence of drug resistance. Further studies using alternative
anti-malarial drugs, including artemisinin derivatives, would be desirable to define optimal management strategies
for P. knowlesi.
Background
The simian malaria parasite Plasmodium knowlesi
causes symptomatic infections in humans throughout
South-east Asia in areas inhabited by its natural maca-
que hosts (Macaca fascicularis and M. nemestrina) and
mosquito vectors of the Anopheles leucosphyrus group
[1-8]. Early trophozoites of P. knowlesi are morphologi-
cally similar to Plasmodium falciparum and all the
other stages resemble those of Plasmodium malariae
[9]. However, unlike P. malariae infections, knowlesi
infections can be severe and even fatal. A recent obser-
vational study found complications in 10% of patients
and a 2% mortality [10].
Previous reports have indicated that patients with
uncomplicated knowlesi malaria respond well to chloro-
quine treatment [1]. In one recent study, the mean
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parasite clearance time of 24 hours for knowlesi malaria
patients was shorter than that for patients infected with
P. falciparum or Plasmodium vivax [9]. There has, how-
ever, been no detailed description of clinical and parasi-
tological responses following treatment and no previous
assessment of antimalarial drug resistance. Such a study
was, therefore, undertaken on patients with knowlesi
and vivax malaria during hospital stay and on a weekly
basis for a month.
Methods
Study site, design and patients
The present study was conducted in Kapit Hospital,
which serves a population of 109,000 in Sarawak, Malay-
sia Borneo, an area with a reported annual malaria inci-
dence of 1.2/1,000. A prospective observational study
design was employed, using the WHO 28 day extended
in vivo drug response assessment [11]. The patients
were selected from a larger cohort participating in a
pilot study and a subsequent observational assessment
of consecutive malaria admissions between May 2006
and December 2007 [10]. Although there are currently
no criteria for severity of infection in knowlesi infected
patients, we have previously defined uncomplicated
cases as those with a parasitaemia of ≤ 100,000/μL
based on falciparum malaria data and the level of immu-
nity in the community. In addition for the present study,
patients that were selected i) had P. knowlesi or P. vivax
monoinfections confirmed by PCR, ii) were at least
15 years of age, iii) were not pregnant, and iv) had no
significant co-morbidities. Those who reported treat-
ment with antimalarial drugs within the preceding
14 days were excluded. All patients gave written
informed consent to participation. The study was
approved by the Medical Research and Ethics Commit-
tee of the Malaysian Ministry of Health.
Antimalarial therapy
All patients were given oral chloroquine 10 mg base/kg
body weight, followed by 5 mg base/kg at 6, 24 and
48 hours (total dose 25 mg base/kg). At 24 hours, and
after glucose-6-phosphate dehydrogenase deficiency had
been excluded (SQMMR 720, R&D diagnostics, Holar-
gos Greece), oral primaquine (15 mg base) was adminis-
tered with food for either two consecutive days for
knowlesi malaria (primarily as a gametocidal agent, as
recommended by the Malaysian Ministry of Health for
patients with P. malariae; there were no treatment
guidelines for P. knowlesi at the time of the study and
PCR confirmation was pending) or 14 days for vivax
malaria (as also recommended by the Malaysian Minis-
try of Health). All drugs were administered by nursing
staff on the medical ward where the patient was
observed until parasite clearance (when two consecutive
blood films 24 hours apart were negative for malaria
parasites).
Clinical and laboratory procedures
At recruitment, a detailed history and clinical examina-
tion were performed and recorded on standardized
forms. Blood samples were taken for routine laboratory
investigations including a full blood count, biochemical
analyses, and blood cultures. In view of the possibility of
cardio-respiratory complications developing during
treatment [10], a baseline chest radiograph and 12 lead
electrocardiogram were performed.
On admission and daily thereafter during hospitalisa-
tion, blood samples were collected on filter paper for
subsequent DNA extraction and polymerase chain reac-
tion (PCR) analyses to identify the species of Plasmo-
dium and determine parasite clearance as described
previously [1,9,12]. Blood was drawn for a full blood
count at 0 and 24 hours. All patients had four-hourly
monitoring of vital signs, daily clinical examination,
daily blood sampling and blood films until parasite and
fever clearance.
In randomly-selected sub-groups of patients with
knowlesi or vivax malaria, additional samples were col-
lected at three or six-hourly intervals for the first
24 hours to enable more detailed characterisation of
initial parasite clearance. Because of the limited number
of patients with P. vivax infections, twice the proportion
was selected for this group compared to that in the
P. knowlesi group.
Following discharge, patients were reviewed on days 7,
14, 21 and 28. Symptoms and clinical signs including
the presence of splenomegaly or hepatomegaly were
recorded, and further blood samples were taken, includ-
ing blood films and filter paper samples for PCR ana-
lyses. If returning to Kapit Hospital for weekly visits was
difficult, patients were asked to attend their nearest
clinic or prepare their own blood spots on filter papers
on days 7, 14 and 21, and to return on day 28 for full
review. When patients did not attend a follow up
appointment, efforts were made to contact them via tel-
ephone, through their employer if at a logging camp,
through people from the same region who were seen at
Kapit Hospital, or by use of the local radio station.
Patients were excluded from the study if they missed a
follow-up visit.
All blood films were examined by two microscopists
who were blinded to all clinical and other data. Parasite
counts were calculated from the number of parasites per
500 white cells, and a density calculated using the
patient’s own white cell count. Stages were classified as
early trophozoites (ring forms and non-pigmented tro-
phozoites), late trophozoites (pigmented parasites with
two or less nuclei), schizonts (pigmented parasites with
Daneshvar et al. Malaria Journal 2010, 9:238
http://www.malariajournal.com/content/9/1/238
Page 2 of 7
more than two nuclei), or gametocytes as previously
described [9].
Outcome measures
Fever clearance time (FCT) was defined as that from
admission to when the axillary temperature reached,
and remained below, 37.5°C for more than 48 hrs. The
time to clearance of 50% and 90% of the admission
parasitaemia (PCT50 and PCT90 respectively) were deter-
mined using least squares linear regression of log-trans-
formed data. The time to a parasitaemia < 5 parasites/
μL and the parasite reduction ratio at 24 hours were
also calculated. Early treatment failure was defined as a
history of fever on day 3, or the development of severe
malaria on day 1 to 3, parasitaemia day 2 greater than
on day 0, pyrexia ≥37.5 °C day 3, parasitaemia on day
3 ≥25% of day 0. Late treatment failure was defined as
severe malaria after day 3 with associated parasitaemia
or pyrexia ≥37.5 °C and parasitaemia present day 4 to
day 28. These definitions are derived from the WHO
criteria for low to moderate transmission areas [11].
Parasite DNA was extracted from the blood spots col-
lected on filter papers daily and at follow-up and was
analysed by nested PCR assays to determine the time to
negative PCR and to assess for parasite recrudescences
and re-infections [1,12].
Statistical analysis
Data were analysed using SPSS software, version 14
(SPSS). Normally distributed variables were expressed as
the mean and standard deviations and comparisons
made using the Student t-test. Non-normally distributed
variables were expressed as the median and interquartile
ranges, and comparisons were made using the Mann-
Whitney U test. Proportions were compared with the
Fisher’s Exact test. A P value < 0.05 was considered
significant in all cases.
Results
During the study period, 145 out of 187 patients
admitted with malaria had single P. knowlesi or P. vivax
malaria infections confirmed by microscopy and PCR.
Of these, 111 (77%) patients had P. knowlesi and 34
(23%) had P. vivax. There were 82 patients with know-
lesi malaria (73.9%) who were eligible for, and agreed to
have, 28-day WHO follow-up and/or six-hourly sam-
pling. Of these, 49 were enrolled for day 28 follow-up
only, 24 for both day 28 follow-up and six-hourly sam-
pling, and nine for six-hourly sampling only. All 33
patients (40%) who consented to six-hourly sampling
completed the study but, of the 73 scheduled for 28-day
in vivo assessment, 13 did not attend for at least one
scheduled review and were excluded. In the vivax group,
29 (85%) of the 34 patients admitted met study criteria
and 23 (79%) had six- hourly blood films taken during
the first 24 hours. The majority of the vivax patients
(65%) were logging-camp workers returning from Asia-
Pacific countries with a higher incidence of malaria than
the Kapit region. Because 14 (61%) patients left the
study area to resume employment elsewhere, there were
insufficient numbers for analysis of the WHO 28 day
extended in vivo drug response.
Subject characteristics at study entry are summarized
in Table 1. The patients in the vivax group were
younger, all male and more likely to have had malaria
previously. Of the patients in the knowlesi group, most
were of Iban ethnicity and had been born in the Kapit
division. All of the communities along the large rivers
and tributaries were represented.
Clinical and parasitological response
All patients in the knowlesi group responded to treat-
ment. By symptom questionnaire, 96% reported sympto-
matic improvement at 24 hours. Late treatment failure
was seen in one patient with vivax malaria with the pre-
sence of a rising parasitaemia on day 4 of treatment.
During treatment, the maximum recorded temperature
was higher in the knowlesi group than the vivax group
(38.9°C versus 38.4°C respectively, P = 0.05), however
the FCTs were similar.
Twenty six out of 33 (79%) patients in the knowlesi
group and 20 of the 23 (87%) patients in the vivax
group had a parasitaemia on admission that was > 1,000
parasite/μL. Assessment of parasite clearance kinetics
Table 1 Demographic features of patients at study entry
Variable P. knowlesi P. vivax P-value
(n = 73) (n = 23)
Age (years) 46.4 ± 13.42 38.5 ± 7.62 < 0.01
Male 58 100 < 0.01
Iban Ethnicity 96 83
Self-reported previous malaria* 22 65 0.01
Duration of illness (days)* 5 [3-7] 3 [1-5] 0.01
Self administered paracetamol 95 78 0.03
Taken traditional remedies 39 13 0.17
Height (metres) 1.54 ± 0.09 1.59 ± 0.07 0.08
Weight (kilograms) Day 0 56.2 ± 10.4 65.3 ± 6.89 < 0.01
Data are percentage of patients, mean ± SD or median [interquartile range]
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was restricted to these patients since parasites had
usually cleared before the 6 hour blood sample in those
with a baseline parasite density < 1,000/μL. The admis-
sion geometric mean parasitaemia of this subgroup was
8,527 parasite/μL and 5,724 parasite/μL for the knowlesi
and vivax patients, respectively.
A mixture of early and late trophozoites (mean 49.5%
and 41.5% respectively) were observed on the admission
blood film in the knowlesi group. However, synchroni-
city was observed in 19 of the 26 patients with up to
100% early trophozoites and 88% late trophozoites,
while the proportion of schizonts ranged from 0 to 39%.
The changing proportion of stages with time is shown
in Figure 1.
The PCT50 and PCT90 were 3.1 and 10.3 hours,
respectively, in the knowlesi group (Table 2). Nine
(27%) patients exhibited a rise in parasitaemia between
baseline and 6 hours, but there was subsequent rapid
clearance in these patients. The median calculated time
to a parasite density below routine detection (< 5/μL),
was 35.8 hours and 62.1 hours in the knowlesi and
vivax groups, respectively (see Figure 2).
The parasite reduction ratio at 24 hours was signifi-
cantly greater in the knowlesi group than the vivax
group (99.4 [97.0-99.9]% vs 95.9 [88.6-98.4]%, P < 0.01).
The percentages of patients with a negative parasitaemia
at 24 hours were 33 (95% CI: 16-31) and 4.6 (95% CI:
0-14) for knowlesi and vivax, respectively.
To explore P. knowlesi dynamics, synchronous infec-
tions were selected, as defined by early or late tropho-
zoite stages comprising > 75% of all parasite forms
(knowlesi group n = 13 and 6 respectively; vivax group
n = 6 and 1). There was no significant differences
between early and late trophozoite predominant parasi-
taemias for the PCT50 and PCT90 in the knowlesi group
[early trophozoites > 75% group: PCT50 2.1 (95% CI:
1.8-2.5) hours; PCT90 7.0 (95% CI: 6.1-8.28) hours. Late
trophozoites > 75% group: PCT50 2.2 (95% CI: 1.7-3.3)
hours; PCT90 7.3 (95% CI: 5.5-11.0) hours].
Three hourly slides performed in nine selected
patients to determine stage specific clearance times
found the PCT50 and PCT90 for late trophozoites to be
shorter (PCT50 2.5 [95% CI: 2.3-2.9]) than other asexual
stages, while gametocytes took longer to clear (PCT50
10.4 [95% CI: 9.0 - 12.2] hours; PCT90 34.4 [95% CI:
29.9-40.4]).
The calculated parasitaemia at the time of fever clear-
ance was significantly lower in the knowlesi group
(P < 0.01). The fever and parasites cleared at a similar
time after treatment in knowlesi infections, while the
fever cleared sooner than parasites in the vivax group.
In vivo response
Parasite clearance, detected by nested PCR assays, took
a median of 3 [interquartile range: 2-3] days in the
knowlesi group. All knowlesi patients were negative
for malaria by PCR on days 7, 14, 21 and 28 indicating
that there was no evidence of resistance of P. knowlesi
to chloroquine and primaquine, re-infection or
recrudescence.
Discussion
The present data demonstrate that conventional doses
of chloroquine are associated with initial parasite clear-
ance that is both faster in knowlesi malaria than vivax
malaria and amongst the most rapid reported for any
human malaria [13-17]. No recurrences of knowlesi
parasitaemia were detected during the 28-day follow-up
period, including by PCR, suggesting either a low inten-
sity of local transmission of P. knowlesi or prophylactic
efficacy of relatively low plasma chloroquine concentra-
tions in the tail of the terminal elimination phase. One
early treatment failure occurred in the vivax group
which was likely due to the increased incidence of chlor-
oquine-resistant P. vivax in Java, Indonesia, where the
patient had resided until three months prior to hospital
admission [18]. The exclusion of R1 resistance in the
vivax group was not possible since too few patients
completed follow up.
Although approximately one-third of the knowlesi
patients experienced a transient rise in parasitaemia dur-
ing the first 6 hours compared with only 13% of patients
from the vivax group, this is likely to reflect several fac-
tors. First, the divided dose chloroquine regimen pro-
duces peak plasma concentrations that occur well after
the first dose. Secondly, even if adequate plasma con-
centrations were reached quickly, the stage specificity of
chloroquine [19] would allow late stage parasites to
mature to schizogony during at least the first few hours
of treatment with production of early ring forms that, as
Figure 1 Change in mean parasite stage distribution during
the first 24 hours of treatment with oral chloroquine.
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evidenced by previous own stage specific clearance
times, are also relatively resistant. Thirdly, the 24 hour
lifecycle of P. knowlesi is half that of P. vivax which
means that, consistent with the relatively high parasite
densities that are regularly observed in P. knowlesi infec-
tions [9], the more rapid maturation of late stage para-
sites would increase the likelihood of an initial rise in
parasitaemia amongst the knowlesi patients. Indeed,
early studies with chloroquine indicated that P. malar-
iae, with an erythrocytic replication cycle of 72 hours,
cleared more slowly than P. vivax [20]. Lastly, since
most of the knowlesi patients denied a previous history
of malaria, a lack of immunity might also have attenu-
ated the effect of chloroquine on initial parasite
clearance.
The study participants were aged > 15 years and lived
and/or worked on tributaries of the Rejang river in close
proximity to the jungle where long-tailed and pig-tailed
macaques have been sighted. Despite this, previous
malaria infections, and in particular recent infections,
were unusual (reported by only 16 of 73 or 22% of the
knowlesi malaria patients). This suggests a low level of
Table 2 Data relating to post-treatment clinical and parasitological response
Variable P. knowlesi (n = 33) P. vivax (n = 23) P value
Admission parasite count (geometric mean per microlitre) 3724 (1,845-7480) 4650 (2,752-7785) 0.6
Fever clearance time (hours) 26.5 [16-34] 20.8 [12-32] 0.32
Percentage given paracetamol during hospital stay 79 52 0.05
Hours before fever clearance 6 [2-13] 4 [1-12] 0.48
Time to clear 50% of admission parasite count (hours) 3.1 (2.84-3.43) 6.3 (5.3-7.8) 0.02
Time to clear 90% of admission parasite count (hours) 10.3 (9.4-11.4) 20.9 (17.6-25.9) 0.02
Calculated time to parasite count < 5 per microlitre (hours) 35.8 [30.8-51.2] 62.1 [43.0-80.2] < 0.01
Parasite reduction ratio at 24 hours 99.3 [50-100] 95.9 [58-100] < 0.01
Percentage negative at 24 hours 33 (16-31) 4.6 (0-14)
Parasite stages (%, range)
Immature trophozoites 49.5 (3.1-100) 64.4 (2.7-98.9) 0.06
Pigmented trophozoites 41.5 (0-88.4) 28.4 (19.1-37.6) 0.09
Schizonts 4.0 (0-38.6) 1.9 (0-36.3) < 0.01
Gametocytes 5.6 (0-32.8) 7.1 (0-53.7) 0.15
Slope of curve for natural logarithm parasite count
All 0.223 ± 0.02 0.110 ± 0.02 0.02
Immature trophozoites 0.182 ± 0.02 0.127 ± 0.03 NT
Mature trophozoites 0.269 ± 0.02 0.147 ± 0.03 NT
Schizont 0.191 ± 0.02 0.02 ± 0.02 NT
Gametocyte 0.061 ± 0.01 0.012 ± 0.03 NT
Data are mean (range), mean ± SD or median [interquartile range] unless stated otherwise. NT not tested.
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knowlesi malaria transmission and, therefore, low back-
ground levels of immunity in the population. The suc-
cessful response to treatment with chloroquine and
primaquine also implies that these infections are chloro-
quine and primaquine naïve, supporting a zoonotic
mode of transmission.
FCTs and PCTs were similar in the knowlesi group,
while fever cleared before parasitaemia in the vivax
group. This suggests that knowlesi malaria has a higher
pyrogenic density than vivax malaria but it may also
reflect differences in immune status between the two
groups. Under Malaysian Ministry of Health treatment
guidelines, oral primaquine was administered to know-
lesi malaria patients for two days in this study as a
gametocidal drug. The effect of this on both asexual and
sexual forms of P. knowlesi is difficult to quantify. Using
primaquine would seem unnecessary since gametocytes
appeared sensitive to chloroquine in the first 24 hours.
P. knowlesi is not known to have a hypnozoite stage
[21]. If persistent liver stages did occur, and consistent
with use of primaquine to prevent relapses of vivax and
ovale malaria, longer duration treatment would be prob-
ably be necessary. Furthermore, there have been three
case reports of chloroquine alone being successful in the
treatment of knowlesi malaria [6,22,23].
Besides chloroquine, other anti-malarial agents have
been used with apparent success for knowlesi malaria.
These include mefloquine [24], quinine [10,25], atova-
quone/proguanil [26] and sulphadoxine-pyrimethamine
[1]. In animal models and in vitro drug studies, P. know-
lesi is sensitive to most antimalarial drugs including
clindamycin [27], naphthoquine [28], sulphonamides
[29], tetracyclines [30], trimethoprim [31] and erythro-
mycin [32]. In Rhesus macaques, a high level of innate
resistance to mefloquine has been seen with the
P. knowlesi W1 strain, while proguanil and pyrimetha-
mine resistance were inducible in experiments with the
P. knowlesi Nuri strain [33-35]. Although knowlesi sen-
sitivity to artemisinin derivatives has not been reported
in man, it seems very likely that it would be successful
as seen in experiments in Rhesus macaques [28,36,37].
In the 1980’s, oral chloroquine was thought to be
more effective than oral quinine as treatment for chloro-
quine sensitive falciparum malaria [38]. Chloroquine was
also effective and well tolerated when administered par-
entally or via nasogastric tube in severe falciparum
malaria [39]. It may be that the use of chloroquine for
severe knowlesi malaria is effective, provided that the
possibility of chloroquine-resistant P. falciparum or
P. vivax co-infection had been excluded. Further studies
using alternative anti-malarial drugs, including artemisi-
nin derivatives, would be desirable to define optimal
management strategies for P. knowlesi.
Conclusion
Chloroquine is an inexpensive, highly effective and well-
tolerated anti-malarial drug for the treatment of natu-
rally-acquired uncomplicated knowlesi malaria in
humans. There is currently no evidence of drug-resistant
P. knowlesi, reflecting a zoonotic mode of transmission
and thus an absence of prior drug pressure. Further care-
fully-designed studies are required to determine whether
chloroquine is effective in severe knowlesi malaria.
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